UCB SA (OTCMKTS:UCBJF - Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 215,500 shares, a decrease of 63.1% from the March 31st total of 584,000 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 1,077.5 days.
UCB Stock Performance
Shares of OTCMKTS:UCBJF remained flat at $150.70 during trading on Tuesday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $176.23 and a 200-day moving average price of $183.04. UCB has a 52 week low of $126.05 and a 52 week high of $209.66.
About UCB
(
Get Free Report)
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
Before you consider UCB, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.
While UCB currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
